ResMed Inc. 10-Q Summary: Quarter Ended March 31, 1996
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1996, and the nine-month period ended March 31, 1996. ResMed Inc. is a Delaware holding company for ResMed Holdings Ltd., an Australian entity that designs, manufactures, and markets devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Principal manufacturing is located in Australia, with distribution in the U.S., U.K., Germany, and Europe.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1996 | Nine Months Ended Mar 31, 1996 |
|---|---|---|
| Net Revenue | $9.36 million | $23.96 million |
| Gross Profit | $4.59 million | $11.97 million |
| Gross Margin | 49% | 50% |
| Net Income | $1.21 million | $3.01 million |
| Diluted EPS | $0.17 | $0.42 |
| Cash from Operations | N/A | $0.96 million |
| Cash & Equivalents (End of Period) | $4.01 million | |
| Marketable Securities | $18.08 million | |
| Long-Term Debt | $0.86 million | |
| Working Capital | $29.86 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 47% ($3.0 million) for the quarter and 43% ($7.2 million) for the nine months compared to the prior year. Growth was driven by increased unit sales of flow generators and accessories in North America and Europe, plus revenue from the Priess acquisition in Germany.
- Profitability: Net income rose 50% for the quarter and 54% for the nine months. However, gross margins declined slightly (from 52% to 49% for the quarter) due to a 5% strengthening of the Australian dollar against the U.S. dollar and product mix changes.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 48% for the quarter, primarily due to headcount growth (from 56 to 90 employees) and legal costs. Research and development (R&D) expenses increased 15% for the quarter due to increased engineering staff.
- Acquisition: On February 7, 1996, the company acquired Dieter W Priess Medizintechnik for $6.35 million in cash, recording $4.46 million in goodwill. Pro forma results suggest the acquisition would have increased nine-month net income to $3.96 million.
- Other Income: Other income surged 209% for the quarter, driven by interest income from IPO proceeds and net foreign exchange gains.
Guidance, Outlook, Risks, and Contingencies
Outlook: Management notes that interim results are not necessarily indicative of full-year results. The company expects continued exposure to foreign exchange rate fluctuations, which may negatively impact consolidated net sales and gross profit margins.
Risks and Contingencies:
- Legal Proceedings: The company is involved in patent litigation in Australia where a patent was revoked on appeal; $300,000 has been accrued for associated costs. Additionally, Respironics Inc. has filed complaints in the U.S. and Australia alleging patent invalidity and unfair trade practices, seeking approximately $730,000 in damages. Management believes these actions will not have a material adverse effect but acknowledges ongoing legal costs.
- Foreign Exchange: The company uses foreign currency option contracts to hedge risks related to sales and manufacturing costs denominated in Australian Dollars, Pound Sterling, and Deutschmarks.
- Contingent Consideration: The Priess acquisition agreement includes potential additional payments of up to $4.0 million over four years contingent on future sales revenues.
Key Facts for Investor Verification
- Verify the impact of the strengthening Australian dollar on future gross margins.
- Monitor the status and potential financial impact of the patent litigation with Respironics Inc. in the U.S. and Australia.
- Assess the integration and revenue contribution of the Priess acquisition against the contingent payment thresholds.
- Review the sustainability of operating cash flows given the significant increase in accounts receivable and inventory levels.